Login to Your Account



Pharma: Clinic Roundup


Thursday, April 19, 2012
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, said a retrospective subanalysis of the 18,113-patient RE-LY trial showed lower rates of intracranial hemorrhage (ICH), including both fatal and traumatic ICH, for Pradaxa (dabigatran etexilate mesylate) capsules 150 mg taken twice daily, compared to warfarin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription